Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

Three years after launching from the lab of University of California, San Francisco chemist Jim Wells, the start-up EpiBiologics has raised $109 million in series B funding to propel its ...

Frankfurt: German agrichemical giant Bayer confirmed to AFP on Wednesday that it was suing American pharmaceutical firms ...

At least 11 million people have gotten sick and 5,000 people have died from the flu this season. Here's what Michigan is ...

A Baltimore jury on Monday ordered Johnson & Johnson (NYSE: JNJ) and its subsidiaries to pay over $1.5 billion to a woman, who claimed that decades of exposure to asbestos in the company's talc-based ...

Monday's verdict comes after the same plaintiffs' firm, Dean Omar, won a $65.5 million talc award on Friday in Minnesota. Johnson & Johnson said it would appeal what it called the 'egregious and ...

Chicago Bears head coach Ben Johnson spoke to media for the first time since his team clinched a playoff berth, and his reaction was exactly what you’d expect. Johnson and the Bears are now at 11-4 on ...

The 37-year-old mom of three said she used the company's baby powder and later developed mesothelioma Charlotte Phillipp is a Weekend Writer-Reporter at PEOPLE. She has been working at PEOPLE since ...

ST. PAUL, Minn. — A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing ...

Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and ...

Getting your Trinity Audio player ready... When they all trickle back under the Nix family roof in Alabama for board-game marathons, the goal is simple. Beat Bo. Because Bo Nix is trying to beat them.

Adrian Esterman receives funding from the NHMRC, MRFF and ARC. COVID rarely rates a mention in the news these days, yet it hasn’t gone away. SARS-CoV-2, the virus that causes COVID, is still with us.